Breast cancer stem cells: are we ready to go from bench to bedside?

被引：35

作者：

Lin, Chieh-Yu ^{[1
]}

Barry-Holson, Keegan Q. ^{[1
]}

Allison, Kimberly H. ^{[1
]}

机构：

[1] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA

来源：

HISTOPATHOLOGY | 2016年 / 68卷 / 01期

关键词：

breast cancer stem cells; cancer stem cells; stem cell therapy; EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-INITIATING CELLS; ACUTE MYELOID-LEUKEMIA; MAMMARY-GLAND; ALDEHYDE DEHYDROGENASE; PHASE-I; MALIGNANT ASCITES; SELF-RENEWAL; TRANSCRIPTION FACTOR; NOTCH INHIBITOR;

D O I：

10.1111/his.12868

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Since the discovery of breast cancer stem cells (BCSCs) more than 10 years ago, a body of exciting research has developed. The intrinsic properties of BCSCs, including self-renewal and the ability to give rise to heterogeneous progeny, make BCSCs a likely source of tumour initiation, heterogeneity, progression and metastasis. BCSCs are also inherently resistant to conventional therapies and are therefore thought to contribute to disease recurrence. In this review, we will focus on both the challenges and recent advances in the characterization of BCSCs with respect to phenotype, molecular signature and their role in the behaviour of the different molecular subtypes of breast cancer. Of most importance is our ability to translate our growing knowledge base into the development of targeted therapies with the goal of reducing adverse outcomes in breast cancer patients.

引用

页码：119 / 137

页数：19

共 154 条

[1]

Abraham BK, 2005, CLIN CANCER RES, V11, P1154

[2] Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion [J].